p53 in 3-D.

-Since 1975, 191 patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). Complete remission rates were 73% for previously untreated patients, 910% for patients previously treated with radiotherapy and 55%0 for patients previously treated with chemotherapy. In 59 patients with advanced disease who received no other treatment, a 5-year survival rate of 66°, was comparable with that achieved by more toxic mustinecontaining combinations. Ch1VPP has few side effects, is easily given to outpatients, and can be combined with elective radiotherapy in selected patients.